Over 40 000 hematopoietic cell transplantations (HCT) are performed worldwide each year, increasing the number of transplant survivors returning to school, the work place and overseas travel. Outbreaks of measles and mumps in immunocompetent individuals and the increased morbidity associated with primary varicella and shingles in older individuals highlight the need for effective vaccination of these vulnerable patients. In current post-HCT vaccination guidelines, only the measles, mumps and rubella vaccine (MMR) and the live-attenuated varicella vaccine (LAVV) designed to prevent primary varicella in varicella zoster seronegative individuals are permissible post HCT and only in select patient groups. All other vaccines, including the shingles vaccines, are contraindicated post HCT. Current data, primarily in pediatric HCT recipients, demonstrate a 60-70% response following a single MMR or LAVV. A two-dose schedule increases the seroconversion rate following these vaccines. This review will highlight published studies on the immunogenicity of MMR and the LAVV, areas in which data on these vaccines are lacking, the criteria for their use in patients transplanted at our center and potential studies to answer questions posed by the growing number of transplant survivors and their physicians on how to safely administer live-attenuated viral vaccines.
INTRODUCTION
Each year, the number of transplant survivors continues to grow. All hematopoietic cell transplantation (HCT) recipients experience immunodeficiency following transplant, the extent and duration of which is dependent primarily on age at transplant, graft source, intensity of the conditioning regimen, incorporation of anti-CD52 (Campath-1H) or CD20 (rituximab) monoclonal antibodies and/or the presence or absence of graft versus host disease (reviewed in Small, 1 Small and Cowan 2 and Ljungman et al. 3 ). Transplant patients ultimately lose immunity to the vaccine-preventable diseases they were immunized against prior to HCT putting them at risk for infection, morbidity and/or mortality following HCT until successfully revaccinated (reviewed in Small, 1 Small and Cowan 2 and Ljungman et al. 3 ). Immunity to measles, mumps and rubella has been shown to wane continuously following HCT and leaves the majority of patients susceptible to infection within 5 years of their transplant. [4] [5] [6] [7] [8] [9] Ljungman et al. 9 showed that patients are more likely to lose their immunity to these viruses if they were vaccinated prior to HCT compared with individuals infected with wild-type measles. Additional risk factors for loss of immunity include younger patient age and history of acute GVHD. 9 Efforts to improve and standardize post-HCT vaccination have been undertaken by several groups since 1995. [10] [11] [12] The most recent guidelines were published in 2009 by the Center for International Blood and Marrow Transplantation Research. 3 These guidelines recommend vaccination with inactivated or toxoid containing vaccines as early as 3-6 months following HCT. In addition, because of the lack of data, all patients, irrespective of immune competence, are vaccinated at fixed times post HCT. Administration of live-attenuated vaccines continues to be recommended X24 months post HCT because of concerns regarding transmission of vaccine-mediated disease and the limited data supporting the safety and immunogenicity of earlier vaccination. 13, 14 Recent years have seen an increase in the number of cases of measles and mumps in the United States. [15] [16] [17] The increase in measles observed in the US in 1991 primarily in adolescents prompted the Advisory Committee on Immunization Practices recommendation of two measles, mumps and rubella vaccine (MMR) doses. 16 In 2011, 90% of the 222 measles cases observed in the United States were imported cases. 17 Although herpes zoster and post-herpetic neuralgia remain a significant cause of morbidity following HCT despite prophylactic medications (reviewed in Small 1 and Small and Cowan 2 ), to date, there are no studies assessing the safety of the live shingles vaccine Zostavax 18 in HCT recipients. Whether the incidence of primary varicella will increase post transplant because of the growing number of patients coming to transplant who have been vaccinated against varicella rather than having had wild-type disease is currently unknown.
MEASLES, MUMPS AND RUBELLA
The potential for severe and even fatal cases of measles has been documented in immunocompromised patients. 19 Although the risk is expected to be similar for patients following HCT, there is a limited number of documented cases. 19, 20 There have been no reported cases of mumps in patients following HCT, but given the recent increase in outbreaks of these viruses, patients following HCT would appear to be at significant risk for infection. 15, 16 Immunity to measles, mumps and rubella has been shown to wane continuously following HCT and leaves the majority of patients susceptible to infection within 5 years of their transplant. [4] [5] [6] [7] [8] [9] Table 1 summarizes the peer-reviewed studies published to date on the use of the trivalent measles, mumps and rubella Live vaccines post HCT CJ Forlenza and TN Small vaccine following autologous and allogeneic HCT, [4] [5] [6] [7] [8] [9] [21] [22] [23] [24] including the pro and cons of each study. To date, there have been no reports of severe adverse reactions following MMR. The majority of studies have shown that the response to measles occurs in approximately 70% of patients when administered 42 years post HCT. Response to mumps was observed in 460% of patients and against rubella in 475%. [4] [5] [6] [7] [8] [9] [21] [22] [23] [24] Two studies have demonstrated that MMR can be safely and effectively administered o2 years post HCT, particularly if the patient has no evidence of active chronic GVHD, is off immunosuppressive therapy and is at least 15 months post HCT. 13, 14, 22 There is limited data on MMR response in recipients of an unrelated, HLA-mismatched-related or cord blood transplant. In 2004, our center published the measles seroconversion rate in 46 recipients of an unrelated or HLA-mismatched family-member transplant performed from 1992 to 2003. 24 Although 30% and 50% of unrelated and HLA-mismatched-related transplant recipients, respectively, failed to respond to measles, there were no adverse events. Figure 1 demonstrates the seroconversion rates of 92 patients immunized with MMR at our center from 2003 to 2011. Patients were vaccinated at a median (range) of 2.4 (1.3-7.3) years post HCT. The median (range) age at immunization was 13.8 (2.1-66.1 years). A total of 59% of patients received a transplant from an unrelated or HLA-mismatched donor and 43% of grafts were T-cell depleted. Eligibility for MMR included no active GVHD, cessation of systemic immunosuppression for at least 6 months, a circulating CD4 cell count 4200 cells/mL, a T-cell response to PHA within the lower limit of normal and response to 41 vaccine post HCT. Overall response to measles, mumps and rubella was 49%, 37% and 92%, respectively. There was a significantly decreased response to measles and mumps, but not rubella, in patients X40 years compared with those immunized o40 years of age. Of the 14 patients who remained seronegative for measles following one MMR, 7 seroconverted following the second vaccine.
VARICELLA/HERPES ZOSTER Primary varicella and more frequently reactivation of varicella zoster virus (VZV) is common following HCT. Reactivation typically occurs within 2 years of HCT with a reported incidence of 18-48%. [25] [26] [27] Reactivation can result in localized cutaneous zoster, disseminated cutaneous or visceral zoster, and can even be fatal. 25, 28 VZV can be further complicated by superinfection and post-herpetic neuralgia in as many as 35% of patients following reactivation. 26 As primary varicella occurring after 10 years of age is associated with increased morbidity 27 and the incidence of shingles following HCT is increased compared with the general population, 25, 28 efforts to reduce these infections post HCT is clearly warranted.
The use of prophylactic low-dose acyclovir or valacyclovir has been shown to be successful in suppressing early reactivation of VZV, but the overall incidence has been unaffected with multiple studies reporting 'rebound' infection occurring with the discontinuation of prophylaxis. 29 Erard et al. 30 demonstrated in a large retrospective study that the use of high-dose acyclovir or valacyclovir was effective in suppressing virus reactivation without this 'rebound' effect. Table 2 summarizes the only four published studies on the live-attenuated varicella vaccine (LAVV) following allogeneic or [31] [32] [33] [34] To date, studies have only included patients o20 years of age and include a total of 34 autologous and 96 allogeneic HCT. The vaccine appears safe when administered according to pre-set milestones of immune competence and was immunogenic in at least 50% of patients. In the two largest studies to date, response after the first vaccine was 55% and 64%, respectively, with additional patients seroconverting following a second vaccine. 33, 34 As two vaccines are currently recommended for healthy individuals, a prospective study in transplant patients using a two-dose schedule is clearly warranted in VZ seronegative patients eligible for vaccination. 35 Although a live-attenuated VZV, Zostavax, 13 was approved in 2005 for prevention of herpes zoster in healthy, immunocompetent individuals X60 years in the United States and 450 years in Europe, this vaccine has not been tested in an immunocompromised population. Zostavax, which is indicated for seropositive patients at risk for shingles, should not be confused with Varivax, utilized in VZ seronegative individuals to prevent chickenpox. The differences between these two vaccines are summarized in Table 3 . A report of a 76-year-old woman receiving chemotherapy for recurrent breast cancer, who developed disseminated varicella following administration of Zostavax, emphasizes the risk of this vaccine in patients whose immune system is not normal. 36 Until studied in the context of a trial, Zostavax is contraindicated in the 2009 Center for International Blood and Marrow Transplantation Research vaccine guidelines. 3 The chickenpox vaccine is allowed in these guidelines, but recommended only for VZ seronegative patients who have no signs of active chronic GVHD, are no longer on any immunosuppressive medications and are 424 months post HCT.
INACTIVATED VZ VACCINES
It should be noted that inactivated vaccines to prevent shingles have been studied in transplant recipients. Hata et al. 37 evaluated the use of a heat-inactivated VZV in patients following autologous HCT. This randomized controlled trial showed that 13% of patients receiving the heat-inactivated vaccine developed herpes zoster within 12 months of HCT, compared with 33% in the control group. An inactivated vaccine would be ideal for use in patients following HCT. Although several such vaccines are undergoing testing in HCT recipients, these vaccines are currently not commercially available.
OTHER LIVE VACCINES
Although there are additional licensed live-attenuated vaccines for use in immunocompetent individuals, they are either not currently recommended for use in HCT patients or there are no data on their immunogenicity in this patient population. These vaccines include the live-attenuated intranasal influenza vaccine, [38] [39] [40] liveattenuated rotavirus vaccine [41] [42] [43] and yellow fever vaccine. 44 The use of the live-attenuated influenza vaccine is not recommended in HCT recipients because of the concern for prolonged viral shedding and respiratory symptoms due to the attenuated influenza strain. This vaccine has been studied in pediatric patients with asymptomatic or mildly symptomatic HIV infection and in oncology patients o21 years of age. Although the vaccine was well tolerated and did not result in prolonged viral shedding, [38] [39] [40] Ab responses following the live-attenuated influenza vaccine were inferior to that observed following the inactivated trivalent influenza vaccine. 39 Therefore, use of this vaccine is unnecessary, given the available inactivated alternative.
Rotavirus infection can caused prolonged and severe symptoms in patients following HCT. 42 However, the use of the rotavirus vaccine in immunocompromised patients is cautioned and there are documented cases of rotavirus infections following administration of the vaccine to infants with SCID. 43 The yellow fever vaccine can cause life-threatening complications, even in healthy individuals. 44 There are case reports of successful vaccination in patients 42 years following HCT. 45, 46 Therefore, its use is generally not indicated unless a patient is traveling to an endemic area and is without concerning risk factors (o2 years following HCT, ongoing immunosuppression or active GVHD).
HOUSEHOLD CONTACTS OF HCT RECIPIENTS WHO HAVE RECEIVED LIVE VACCINES/ISOLATION OF HCT RECIPIENTS FROM OTHER HCT PATIENTS
Immunocompetent family members and household contacts of HCT recipients should not receive the oral polio virus, small pox vaccine or the live influenza vaccine because of the concerns regarding transmission of vaccine virus to an immunocompromised host. The 2009 Center for International Blood and Marrow Transplantation Research guideline recommends that MMR be given to household contacts who are X12 months old and are not pregnant or immunocompromised as no evidence exists that liveattenuated vaccine-strain viruses in MMR vaccine are transmitted from person-to-person. 3 The guidelines also recommend that Varivax be given to susceptible, eligible household contacts because of the greater risk and morbidity from acquisition of wildtype varicella from a VZ seronegative family member or household contact compared with transmission and complications from the attenuated vaccine strain. 3 If a post-vaccination rash develops within 42 days of vaccination, the vaccinee should avoid contact with HCT recipients until the rash has resolved or at least totally crusted over.
INSTITUTIONAL GUIDELINES AT THE MEMORIAL SLOAN KETTERING CANCER CENTER
At our center, live-attenuated vaccines are given 18-24 months post HCT. Criteria for receiving a live vaccine include no active GVHD, cessation of systemic immunosuppression X6 months prior to vaccination, a circulating CD4 cell count 4200 cells/mL, Live vaccines post HCT CJ Forlenza and TN Small a T-cell response to PHA within the lower limit of normal and response to at least two non-live vaccine administered post HCT. MMR is given to patients o21 years of age and to measlessusceptible adults as per the 2009 Center for International Blood and Marrow Transplantation Research guidelines. 3 We administer two MMR vaccines, a minimum of 3 months apart, as well as two LAVV, a minimum of 1 month apart. We generally do not administer MMR, and the LAVV together due to concerns of increased side effects. We measure pre-and post-vaccine titers in all patients. If patients have no response after two vaccines, we reassess their in vitro immune reconstitution, including total and naïve CD4 cells, T-cell-proliferative response against PHA, 47 and serum IgG subtypes. If these values are normal for age, we recommend waiting at least 6 months before administering a third and final vaccine. For varicella, we measure specific T-and B-cell responses. For patients 421 years of age, we only immunize with MMR or the LAVV if the patient is seronegative.
EVALUATION OF CURRENT EVIDENCE AND FUTURE DIRECTIONS
The 2009 CIBMT guidelines call for the application of a uniform vaccination schedule for all types of HCT for simplicity and cites lack of evidence for more specific guidelines. 3 All vaccine guidelines, including those published in 2009, 3 acknowledge the variability in immune reconstitution following alternative donor transplants (reviewed in Small 1 ). Vaccination based on fixed times post HCT may be sufficient for highly immunogenic vaccines, such as polio, but for live-attenuated vaccines, although vaccination prior to the acquisition of critical T-and B-cell subpopulations may hinder the response. It is hoped that in the next 5 years, prospective multi-center, potentially international trials assessing the immunogenicity and safety of live-attenuated vaccines will be undertaken particularly in individuals 420 years at vaccination time. Studies should include assessments of in vitro parameters of immune reconstitution to determine whether surrogate markers of immune reconstitution can predict vaccine response and durability of response. In vitro correlates of vaccine responses might allow earlier revaccination of patients with the requisite T-and B-cell populations and prevent premature vaccination and/or risk in patients unable to respond. It may also allow us to determine who can safely receive the shingles vaccine, a vaccine which has not been formally tested in any potentially compromised population.
